发明名称 |
Peptidomimetic macrocycles |
摘要 |
Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins; and methods of identifying and making such improved polypeptides. |
申请公布号 |
US9175045(B2) |
申请公布日期 |
2015.11.03 |
申请号 |
US201313957667 |
申请日期 |
2013.08.02 |
申请人 |
Aileron Therapeutics, Inc. |
发明人 |
Nash Huw M.;Annis David Allen;Kapeller-Libermann Rosanna;Sawyer Tomi K.;Kawahata Noriyuki |
分类号 |
A61K38/10;A61K38/12;C07K14/00;C07K7/08;C07K7/54;C07K14/47;G01N33/50 |
主分类号 |
A61K38/10 |
代理机构 |
Wilson Sonsini Goodrich & Rosati |
代理人 |
Wilson Sonsini Goodrich & Rosati |
主权项 |
1. A method of preparing a polypeptide with optimized cellular efficacy in human whole blood, the method comprising:
(a) providing a parent polypeptide comprising a cross-linker connecting a first amino acid and a second amino acid of the parent polypeptide, and wherein the parent polypeptide penetrates cell membranes by an energy-dependent process and binds to an intracellular target; (b) producing a modified polypeptide having the same sequence as the parent polypeptide sequence except that at least one acidic side chain in the modified polypeptide is replaced with a neutral side chain; wherein the acidic side chain in the parent polypeptide is adjacent to a large hydrophobic side chain and is not essential for target binding, and wherein the modified polypeptide comprises a cross-linker connecting a first amino acid and a second amino acid of the modified polypeptide; (c) measuring an in vitro efficacy of the modified polypeptide in a whole cell assay wherein activity of the modified polypeptide is mediated by binding of the modified polypeptide to the intracellular target, in the presence and absence of human serum; (d) calculating an apparent affinity (Kd*) of the modified polypeptide to human serum proteins and an EC50 of the modified polypeptide; and (e) selecting the modified polypeptide as an optimized polypeptide if the modified polypeptide has a higher Kd* and an equal or lower EC50 than the parent polypeptide. |
地址 |
Cambridge MA US |